Following its recent acquisition from Novacyt Group, the Milton based pathology services company formerly known as Lab 21, has relaunched as Cambridge Clinical Laboratories (CCL). The new owner, Cambridge Pathology BV, has already invested thousands into the company in new equipment and staff. 

For over fifteen years CCL (in its former guise) has been quietly helping people every day, positively impacting their health by providing fast and accurate Oncology and Virology diagnostics to improve the chances of them receiving successful treatment. 

CEO, Dr Anthony Cooke says: “This is an exciting time for our company. Now with this new investment and support we will continue to expand our current offering of services in Oncology and Virology but also begin to offer new services in new areas such as Autoimmune Disease, and Sexual Health. 

“We are living in almost revolutionary times with regards to personalised healthcare diagnostics and specifically targeted therapeutics and we plan for CCL to be involved in that revolution, being a future leader in service provision. The age of personalised medicine is now well established. Everyone needs to be seen and treated as an individual. As diagnostics and therapeutics develop to meet this rapidly changing need CCL will be there to provide a first-class service alongside those state-of-the-art tests and treatments.”

Since the company begun, in 2005, over 65,000 tests have been carried out and over 300 customers supported. The team are all long standing employees and are both excited and committed to the future of the company. They are supported by industry experts Professor Dean A. Fennell, and Professor Clive Loveday. 

CCL also plans to partner with diagnostic manufacturers, from around the globe, to provide the most effective, state of the art diagnostic tests to help the NHS and private healthcare in the UK and abroad, while also working with global pharmaceutical companies to help develop and successfully introduce the latest companion diagnostics into the marketplace.

Press contact:
Kelly Morel, PR Manager, kelly@happycommunications.co.uk, 07488 386812

Editors notes:
From 11 November 2019, the company will be publicly known as Cambridge Clinical Laboratories (CCL).

CCL started its journey as Lab 21 in 2005. The objective for the company was to be a lab for the 21st century – a lab that would be an early adopter of new technologies for diagnostics. To offer personalised medicine and introduce new novel technologies and assays to help UK healthcare. This is still very much the aim today. 

Owner, Cambridge Pathology BV, is investing and fully engaged in the company’s strategy for the future. 

CCL provides healthcare professionals worldwide with the most advanced testing services from their UKAS accredited facilities in the heart of scientific development, Cambridge, UK. 

Available for interview:
CEO - Dr Anthony Cooke
Tony has nearly 40 years’ experience in the diagnostics industry and vast business experience. That alongside his loyalty and relationship with the company (he was a founding member of Lab 21 back in 2005) makes him the perfect person to guide the company through the next stage of its journey. He plans to expand the portfolio and widen the geographic reach, working with the owners on where to invest. Tony is looking to develop closer relationships with diagnostic and pharma companies to expand the offering to the NHS and private healthcare providers in the UK, but also expand the company’s international presence.

For company news and further information on the team visit www.camclinlabs.co.uk 

Or follow their social media feeds:

• Twitter @camclinlabs

• LinkedIn @Cambridge Clinical Laboratories